Email updates

Keep up to date with the latest news and content from Cardiovascular Diabetology and BioMed Central.

Open Access Highly Accessed Original investigation

A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study

Toshiyuki Hibuse1, Norikazu Maeda2*, Ken Kishida23*, Takekazu Kimura2, Tomoko Minami2, Eriko Takeshita1, Ayumu Hirata2, Yasuhiko Nakagawa1, Susumu Kashine2, Akemi Oka4, Masumi Hayashi4, Hitoshi Nishizawa2, Tohru Funahashi25 and Iichiro Shimomura2

Author Affiliations

1 Department of Internal Medicine, Suita Municipal Hospital, 2-13-20, Katayamacho, Suita, Osaka 564-0082, Japan

2 Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2 B-5, Yamada-oka, Suita, Osaka 565-0871, Japan

3 Kishida Clinic, 5-6-3, Honmachi, Toyonaka, Osaka 560-0021, Japan

4 Department of Clinical Trial Management, Suita Municipal Hospital, 2-13-20, Katayamacho, Suita, Osaka 564-0082, Japan

5 Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, 2-2-B, Yamada-oka, Suita, Osaka 565-0871, Japan

For all author emails, please log on.

Cardiovascular Diabetology 2014, 13:96  doi:10.1186/1475-2840-13-96

Published: 24 May 2014

Abstract

Background

The dipeptidyl-peptidase-IV (DPP-4) inhibitors, including sitagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM). Adiponectin, an adipocyte-derived circulating protein, has anti-atherosclerotic and anti-diabetic properties and is effectively elevated in bloodstream by thiazolidinediones, an insulin sensitizer. However, the effect of sitagliptin treatment on serum adiponectin level in T2DM has not fully elucidated in Japanese T2DM patients. The aim of the present study was to examine the effect of sitagliptin treatment on serum adiponectin levels in T2DM subjects.

Methods

Twenty-six consecutive Japanese T2DM outpatients were recruited between April 2011 and March 2013, and randomized into the control (conventional treatment, n = 10) group and sitagliptin treatment group (n = 16). Serum adiponectin was measured by enzyme-linked immunosorbent assay.

Results

Indices of glycemic control, such as hemoglobin A1c, glycated albumin, and 1.5-anhydro-D-glucitol, were significantly improved after the three-month treatment in both the control and sitagliptin groups. Serum adiponectin level was significantly increased in sitagliptin group from 6.7 ± 0.8 to 7.4 ± 1.0 μg/mL without change of body mass index (p = 0.034), while serum adiponectin level was not altered in the control group (p = 0.601).

Conclusion

In Japanese T2DM patients, serum adiponectin level was elevated by three-month treatment with sitagliptin without change of body weight.

Trial registration

UMIN000004721

Keywords:
Sitagliptin; Adiponectin; DPP4 inhibitor; Inctrein; Diabetes; Oxidative stress